Dr. Hope Rugo's Interview with Dennis Slamon, MD
Description
Interviews with Summit Director Hope Rugo, MD
MaTOS Breast 2025 | Masters in Therapeutic Oncology Summit | Breast Edition
Dr. Hope Rugo interviews key note speaker, Dr. Dennis Slamon, a pioneer in breast cancer treatment, about his groundbreaking work on HER2-positive breast cancer. Slamon discusses the development of trastuzumab, which transformed HER2 from a poor to a favorable prognosis, and the challenges of next-generation HER2 therapies due to off-target effects. He also highlights the success of CDK4/6 inhibitors in hormone receptor-positive breast cancer, noting improvements in safety through dose reduction. Slamon's ongoing research involves identifying new targets using advanced platforms, aiming to continue revolutionizing breast cancer treatment.
United States
